[A19-54] Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12
Last updated 15.08.2019
Commission awarded on 24.06.2019 by the Federal Joint Committee (G-BA).
Treatment-naive adults with intermediate or poor-risk advanced renal cell carcinoma
Conclusion of dossier assessments A19-11 and A19-12 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A19-12||Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A19-11||Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|